← Back to patent-cliff list
Talaporfin Sodium
Tier C — Watch / tradeTalaporfin Sodium
-
Originator
2003
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Not applicable
Brand：Aptocine, Laserphyrin
Indications (approved)：Lung cancer, 脑癌
Regional status
US
Discontinued
2003-10-01
EU
No progress
2006-07-01
China
Phase I
2009-02-04
Japan
Approved
2003-10-16
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Talaporfin Sodium?
Approved indications include: Lung cancer, 脑癌.
When does the Talaporfin Sodium patent expire?
No public expiry year is available for Talaporfin Sodium yet; this page updates once verified.
How do I get a quote for Talaporfin Sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27